The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

A large analysis of weight-loss drugs like Ozempic and Wegovy has surprised health researchers, who found links to multiple new benefits – and some new side effects.

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...